Preclinical and Clinical Development of Angiotensin Peptides (Mas/Ang(1-7)/ACE-2): Future Clinical Application

Kathleen E. Rodgers; Gere S. diZerega

doi:10.1016/B978-0-12-801364-9.00041-9

Preclinical and Clinical Development of Angiotensin Peptides (Mas/Ang(1-7)/ACE-2): Future Clinical Application

Kathleen E. Rodgers, Gere S. diZerega

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Evidence points to a role for the renin-angiotensin system in the regulation of hematopoiesis. We showed that angiotensin 1-7 (A(1-7)) accelerated recovery and engraftment of bone marrow progenitors. Multilineage bone marrow recovery results in platelet and white blood cell recovery. The effects of A(1-7) are synergistic with Neupogen® and Epogen, both in the bone marrow and in the periphery. Treatment with A(1-7) reduces the dose of Neupogen required to stimulate recovery following myelosuppression. Clinical studies show that TXA127 (clinical formulation of A(1-7)) treatment restores the hematopoietic parameters after chemotherapy, allows the maintenance of chemotherapy dose intensity, and increases progenitor mobilization in combination with Neupogen. In conclusion, A(1-7) is an effective, multilineage stimulant of bone marrow recovery.

Original language	English (US)
Title of host publication	The Protective Arm of the Renin Angiotensin System (RAS)
Subtitle of host publication	Functional Aspects and Therapeutic Implications
Publisher	Elsevier Inc.
Pages	287-292
Number of pages	6
ISBN (Electronic)	9780128014851
ISBN (Print)	9780128013649
DOIs	https://doi.org/10.1016/B978-0-12-801364-9.00041-9
State	Published - Apr 22 2015
Externally published	Yes

Keywords

Angiotensin 1-7
Bone marrow
Drug development
Hematopoiesis
Renin-angiotensin system

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-12-801364-9.00041-9

Cite this

@inbook{34369ee2596e4e0cba17824396d73f39,

title = "Preclinical and Clinical Development of Angiotensin Peptides (Mas/Ang(1-7)/ACE-2): Future Clinical Application",

abstract = "Evidence points to a role for the renin-angiotensin system in the regulation of hematopoiesis. We showed that angiotensin 1-7 (A(1-7)) accelerated recovery and engraftment of bone marrow progenitors. Multilineage bone marrow recovery results in platelet and white blood cell recovery. The effects of A(1-7) are synergistic with Neupogen{\textregistered} and Epogen, both in the bone marrow and in the periphery. Treatment with A(1-7) reduces the dose of Neupogen required to stimulate recovery following myelosuppression. Clinical studies show that TXA127 (clinical formulation of A(1-7)) treatment restores the hematopoietic parameters after chemotherapy, allows the maintenance of chemotherapy dose intensity, and increases progenitor mobilization in combination with Neupogen. In conclusion, A(1-7) is an effective, multilineage stimulant of bone marrow recovery.",

keywords = "Angiotensin 1-7, Bone marrow, Drug development, Hematopoiesis, Renin-angiotensin system",

author = "Rodgers, {Kathleen E.} and diZerega, {Gere S.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = apr,

day = "22",

doi = "10.1016/B978-0-12-801364-9.00041-9",

language = "English (US)",

isbn = "9780128013649",

pages = "287--292",

booktitle = "The Protective Arm of the Renin Angiotensin System (RAS)",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Preclinical and Clinical Development of Angiotensin Peptides (Mas/Ang(1-7)/ACE-2)

T2 - Future Clinical Application

AU - Rodgers, Kathleen E.

AU - diZerega, Gere S.

PY - 2015/4/22

Y1 - 2015/4/22

N2 - Evidence points to a role for the renin-angiotensin system in the regulation of hematopoiesis. We showed that angiotensin 1-7 (A(1-7)) accelerated recovery and engraftment of bone marrow progenitors. Multilineage bone marrow recovery results in platelet and white blood cell recovery. The effects of A(1-7) are synergistic with Neupogen® and Epogen, both in the bone marrow and in the periphery. Treatment with A(1-7) reduces the dose of Neupogen required to stimulate recovery following myelosuppression. Clinical studies show that TXA127 (clinical formulation of A(1-7)) treatment restores the hematopoietic parameters after chemotherapy, allows the maintenance of chemotherapy dose intensity, and increases progenitor mobilization in combination with Neupogen. In conclusion, A(1-7) is an effective, multilineage stimulant of bone marrow recovery.

AB - Evidence points to a role for the renin-angiotensin system in the regulation of hematopoiesis. We showed that angiotensin 1-7 (A(1-7)) accelerated recovery and engraftment of bone marrow progenitors. Multilineage bone marrow recovery results in platelet and white blood cell recovery. The effects of A(1-7) are synergistic with Neupogen® and Epogen, both in the bone marrow and in the periphery. Treatment with A(1-7) reduces the dose of Neupogen required to stimulate recovery following myelosuppression. Clinical studies show that TXA127 (clinical formulation of A(1-7)) treatment restores the hematopoietic parameters after chemotherapy, allows the maintenance of chemotherapy dose intensity, and increases progenitor mobilization in combination with Neupogen. In conclusion, A(1-7) is an effective, multilineage stimulant of bone marrow recovery.

KW - Angiotensin 1-7

KW - Bone marrow

KW - Drug development

KW - Hematopoiesis

KW - Renin-angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=84940055340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940055340&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801364-9.00041-9

DO - 10.1016/B978-0-12-801364-9.00041-9

M3 - Chapter

AN - SCOPUS:84940055340

SN - 9780128013649

SP - 287

EP - 292

BT - The Protective Arm of the Renin Angiotensin System (RAS)

PB - Elsevier Inc.

ER -

Preclinical and Clinical Development of Angiotensin Peptides (Mas/Ang(1-7)/ACE-2): Future Clinical Application

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this